Gritstone vaccine (GRT-R910) trial

Project summary:

This is the UK arm of a clinical trial of the vaccine (GRT-R910) produced by US-based biotechnology company Gritstone bio, Inc. 

The trial will involve 20 people aged 60 and over, who previously received two doses of the AstraZeneca vaccine, and will take place at the NIHR Manchester Clinical Research Facility at Manchester Royal Infirmary, part of Manchester University NHS Foundation Trust (MFT). 

Funders

Health Innovation Manchester

Leader researcher:

Professor Andrew Ustianowski

Lead institution:

NIHR Manchester Clinical Research Facility